Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Post SABCS local therapy and radiology.

Fitzal F.

Memo. 2018;11(3):213-216. doi: 10.1007/s12254-018-0403-3. Epub 2018 May 15. Review.

2.

Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy.

Weber WP, Haug M, Kurzeder C, Bjelic-Radisic V, Koller R, Reitsamer R, Fitzal F, Biazus J, Brenelli F, Urban C, Paulinelli RR, Blohmer JU, Heil J, Hoffmann J, Matrai Z, Catanuto G, Galimberti V, Gentilini O, Barry M, Hadar T, Allweis TM, Olsha O, Cardoso MJ, Gouveia PF, Rubio IT, de Boniface J, Svensjö T, Bucher S, Dubsky P, Farhadi J, Fehr MK, Fulco I, Ganz-Blättler U, Günthert A, Harder Y, Hauser N, Kappos EA, Knauer M, Landin J, Mechera R, Meani F, Montagna G, Ritter M, Saccilotto R, Schwab FD, Steffens D, Tausch C, Zeindler J, Soysal SD, Lohsiriwat V, Kovacs T, Tansley A, Wyld L, Romics L, El-Tamer M, Pusic AL, Sacchini V, Gnant M.

Breast Cancer Res Treat. 2018 Sep 4. doi: 10.1007/s10549-018-4937-1. [Epub ahead of print] Review.

PMID:
30182349
3.

Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis.

Valachis A, Mamounas EP, Mittendorf EA, Hayashi N, Ishitobi M, Natoli C, Fitzal F, Rubio IT, Tiezzi DG, Shin HC, Anderson SJ, Hunt KK, Matsuda N, Ohsumi S, Totomi A, Nilsson C.

Cancer. 2018 Jul 15;124(14):2923-2930. doi: 10.1002/cncr.31518. Epub 2018 May 3.

PMID:
29723396
4.

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M; ABCSG.

Ann Surg. 2018 Apr 24. doi: 10.1097/SLA.0000000000002771. [Epub ahead of print]

PMID:
29697452
5.

Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.

Strobl S, Wimmer K, Exner R, Devyatko Y, Bolliger M, Fitzal F, Gnant M.

Curr Treat Options Oncol. 2018 Mar 12;19(4):18. doi: 10.1007/s11864-018-0535-z. Review.

PMID:
29527635
6.

Optimal duration of adjuvant endocrine therapy: how to apply the newest data.

Wimmer K, Strobl S, Bolliger M, Devyatko Y, Korkmaz B, Exner R, Fitzal F, Gnant M.

Ther Adv Med Oncol. 2017 Nov;9(11):679-692. doi: 10.1177/1758834017732966. Epub 2017 Oct 27. Review.

7.

Sized Influences Nodal Status in Women Aged #70 with Endocrine Responsive Breast Cancer.

Fitzal F, Helfgott R, Moinfar F, Gnant M.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):555-556. doi: 10.1245/s10434-017-6156-0. Epub 2017 Nov 20. No abstract available.

PMID:
29159741
8.

First international consensus conference on standardization of oncoplastic breast conserving surgery.

Weber WP, Soysal SD, El-Tamer M, Sacchini V, Knauer M, Tausch C, Hauser N, Günthert A, Harder Y, Kappos EA, Schwab F, Fitzal F, Dubsky P, Bjelic-Radisic V, Reitsamer R, Koller R, Heil J, Hahn M, Blohmer JU, Hoffmann J, Solbach C, Heitmann C, Gerber B, Haug M, Kurzeder C.

Breast Cancer Res Treat. 2017 Aug;165(1):139-149. doi: 10.1007/s10549-017-4314-5. Epub 2017 Jun 3.

PMID:
28578506
9.

Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials.

Krois W, Romar AK, Wild T, Dubsky P, Exner R, Panhofer P, Jakesz R, Gnant M, Fitzal F.

Breast Cancer Res Treat. 2017 Jul;164(2):421-427. doi: 10.1007/s10549-017-4255-z. Epub 2017 May 2.

10.

Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.

Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Moinfar F, Gruber C, Petru E, Bartsch R, Tendl KA, Fuchs D, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2017 Jul 15;23(14):3676-3683. doi: 10.1158/1078-0432.CCR-16-2373. Epub 2017 Jan 31.

11.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.

PMID:
26040499
12.

Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer.

Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C, Sattlberger C, Mader RM, Zagouri F, Sparber C, Fitzal F, Gnant M, Rottenfusser A, Zielinski CC, Preusser M, Steger GG, Bartsch R.

Breast Care (Basel). 2014 Oct;9(5):344-8. doi: 10.1159/000368330. Erratum in: Breast Care (Basel). 2016 Feb;11(1):20.

13.

Lymph node staging in invasive breast cancer.

Fitzal F, Galimberti V, Kühn T, Rutgers EJ, Untch M.

Breast Care (Basel). 2014 Jul;9(3):211-4. doi: 10.1159/000365315. No abstract available.

14.

Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.

Berghoff AS, Bartsch R, Preusser M, Ricken G, Steger GG, Bago-Horvath Z, Rudas M, Streubel B, Dubsky P, Gnant M, Fitzal F, Zielinski CC, Birner P.

Breast. 2014 Oct;23(5):637-43. doi: 10.1016/j.breast.2014.06.011. Epub 2014 Jul 10.

PMID:
25017122
15.

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.

Foedermayr M, Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M, Dubsky P, Fitzal F, Gnant M, Steger GG, Weltermann A, Zielinski CC, Zach O, Bartsch R.

Cancer Chemother Pharmacol. 2014 Apr;73(4):771-8. doi: 10.1007/s00280-014-2404-1. Epub 2014 Feb 14.

PMID:
24526178
16.

Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo Classification.

Panhofer P, Ferenc V, Schütz M, Gleiss A, Dubsky P, Jakesz R, Gnant M, Fitzal F.

Int J Surg. 2014;12(4):334-9. doi: 10.1016/j.ijsu.2014.01.012. Epub 2014 Jan 31.

17.

German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla in breast cancer.

AGO; DGS; SGS; ÖGS; Panelists; Executive Board Members, Hoffmann J, Souchon R, Lebeau A, Öhlschlegel C, Gruber G, Rageth C, Weber W, Harbeck N, Janni W, Kreipe H, Fitzal F, Resch A, Bago-Horvath Z, Peintinger F.

Eur J Cancer. 2013 Jul;49(10):2277-83. doi: 10.1016/j.ejca.2013.01.034. Epub 2013 Mar 13.

PMID:
23490652
18.

Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer.

Knauer M, Gnant M, Fitzal F.

Breast Care (Basel). 2012 Feb;7(1):61-66. Epub 2012 Feb 20.

19.

Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.

Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F, Gnant M, Zielinski CC, Steger GG.

Eur J Cancer. 2012 Sep;48(13):1932-8. doi: 10.1016/j.ejca.2012.03.002. Epub 2012 Mar 27.

PMID:
22459763
20.

Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.

Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M.

J Clin Oncol. 2012 Mar 1;30(7):722-8. doi: 10.1200/JCO.2011.36.8993. Epub 2012 Jan 23.

PMID:
22271481

Supplemental Content

Loading ...
Support Center